Patents Issued in February 5, 2019
  • Patent number: 10195150
    Abstract: In some aspects of the present invention is a formulation comprising a solid dispersion or intimate mixture of a poorly water soluble drug and an ionic polymer surprisingly exhibiting fast disintegration of tablet.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: February 5, 2019
    Assignee: Kashiv Pharma, LLC
    Inventors: Jelena Djordjevic, Murali Mohan Bommana, Wantanee Phuapradit, Navnit H. Shah, Christopher A. Pizzo
  • Patent number: 10195151
    Abstract: The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: February 5, 2019
    Assignee: Jazz Pharmaceuticals International III Limited
    Inventors: Clark Patrick Allphin, Edwin Gerard Walsh
  • Patent number: 10195152
    Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: February 5, 2019
    Assignee: PURDUE PHARMA L.P.
    Inventors: Rama Abu Shmeis, Sheetal R. Muley, Xiaohong Shen, Zhixin Zong
  • Patent number: 10195153
    Abstract: The present disclosure relates to an oral, immediate release, abuse deterrent pill containing at least one active pharmaceutical ingredient susceptible to abuse which is homogenously spread throughout a carrier matrix used to deter abuse. The pill is prepared using hot melt extrusion and a forming unit through a continuous process. The formed pill is abuse deterrent to parenteral administration due at least to particle size, viscosity, or purity limitations.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: February 5, 2019
    Assignee: Pharmaceutical Manufacturing Research Services, Inc.
    Inventors: Edwin R. Thompson, Eric R. Thompson, Nicholas R. Myslinski, Steven F. Kemeny
  • Patent number: 10195154
    Abstract: A method for easily producing orodispersible tablets that secure an eluting behavior of a principal agent in the digestive tract and mask unpleasant taste in the oral cavity is provided. Provided is a method for producing orodispersible tablets which includes mixing an additive to a principal agent to form principal agent particles as a granulation process, coating the principal agent particles with a coating agent to form coated particles as a coating process, and tableting the coated particles to form tablets as a tableting process, wherein the additive used in the granulation process contains a pH regulator, and the coating agent used in the coating process contains a pH-dependent polymer dissolving at pH 5 or more.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: February 5, 2019
    Assignee: Nipro Corporation
    Inventors: Yohei Hoashi, Naohisa Katayama, Shunsuke Daidouji
  • Patent number: 10195155
    Abstract: The present disclosure relates to a tumor-targeted drug delivery system, comprising a tumor-targeted drug carrier and a tumor-treating drug, wherein the tumor-targeted drug carrier comprises full heavy-chain human ferritin. The present disclosure also relates to a method for preparing the tumor-targeted drug delivery system comprising: depolymerizing a polymerized full heavy-chain human ferritin; adding a tumor-treating drug to the depolymerized full heavy-chain human ferritin so as to bind the tumor-treating drug to the depolymerized full heavy-chain human ferritin; and re-polymerizing the depolymerized full heavy-chain human ferritin bound with the tumor-treating drug to form a nanoparticle.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: February 5, 2019
    Assignee: Institute of Biophysics, Chinese Academy of Sciences
    Inventors: Xiyun Yan, Kelong Fan, Minmin Liang, Fei Wang, Demin Duan, Dexi Zhang, Jing Feng, Dongling Yang
  • Patent number: 10195156
    Abstract: The disclosure features amino lipids and compositions involving the same. Nanoparticle compositions include an amino lipid as well as additional lipids such as phospholipids, structural lipids, PEG lipids, or a combination thereof. Nanoparticle compositions further including therapeutic and/or prophylactic agents such as RNA are useful in the delivery of therapeutic and/or prophylactic agents to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: February 5, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Kerry E. Benenato, William Butcher
  • Patent number: 10195157
    Abstract: A delivery system containing an active agent within a polymeric material formed from a thermoplastic composition is provided. Through selective control over the particular nature of the thermoplastic composition, as well as the manner in which it is formed, the present inventors have discovered that a porous network can be created that contains a plurality of micropores and nanopores. The ability to create such a multimodal pore size distribution can allow the delivery rate of an active agent to be tailored for a particular use.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: February 5, 2019
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Vasily A. Topolkaraev, Neil T. Scholl, Ryan J. McEneany, Thomas A. Eby
  • Patent number: 10195158
    Abstract: Biocompatible and biodegradable nanofibers are provided. The biocompatible and biodegradable nanofibers include an oil based polyesteramide, a protein/polysaccharide, and a pharmaceutical drug useful for wound healing and biomedical applications thereof.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: February 5, 2019
    Assignee: Council of Scientific & Industrial Research
    Inventor: Rathna Venkata Naga Gundloori
  • Patent number: 10195159
    Abstract: Processes for preparing extracts of natural products such as plant material, and for preparing purified extracts from crude extracts of natural products, by extraction with hot gas. Apparatus suitable for use in preparing extracts of natural products are also described.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: February 5, 2019
    Assignee: GW Pharma Limited
    Inventors: Brian Anthony Whittle, Geoffrey Guy, David Victor Downs, David W. Pate
  • Patent number: 10195160
    Abstract: The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: February 5, 2019
    Assignee: Dermavant Sciences GmbH
    Inventors: Sujatha D. Sonti, Joey Roger Thomas, Jon Lenn, Leandro Santos, Justin Whiteman, Michael Quinn Doherty, Mary Bedard, Piyush Jain
  • Patent number: 10195161
    Abstract: The present invention relates to methods of treating Leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: February 5, 2019
    Assignee: BIOELECTRON TECHNOLOGY CORPORATION
    Inventor: Guy M. Miller
  • Patent number: 10195162
    Abstract: The present invention provides a tolterodine-containing patch in which an adhesive layer is laminated on a backing, characterized in that the adhesive layer is obtainable by adding tolterodine to an adhesive base comprising a rubber adhesive, a tackifier resin, and a softener, wherein the tolterodine is present in the form of a free base in the adhesive base.
    Type: Grant
    Filed: December 25, 2012
    Date of Patent: February 5, 2019
    Assignee: TEIKOKU SEIYAKU CO., LTD.
    Inventors: Taiki Shibata, Kensuke Murata, Kenichi Hattori, Shinji Tanaka
  • Patent number: 10195163
    Abstract: Compositions containing monoamine oxidase inhibitors prepared by removal of alcohol from agave-derived beverages are disclosed.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: February 5, 2019
    Assignee: ROAR HOLDING LLC
    Inventor: Robert W. Brocia
  • Patent number: 10195164
    Abstract: Methods, compositions of matter, and kits for treatment of breast cancer, and in particular for inflammatory breast cancer, in a patient are disclosed. The methods can include administering a redox modulating agent to the patient. The redox modulating agent can be disulfiram.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: February 5, 2019
    Assignee: Duke University
    Inventor: Gayathri Devi
  • Patent number: 10195165
    Abstract: Methods of treating Prader-Willi syndrome in a subject in need of treatment are provided. The methods include administering to the subject an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R, R?, X, Y and Z are defined as set forth in the specification. In embodiments, an effective amount of captodiamine or a pharmaceutically acceptable salt thereof is administered to the subject.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: February 5, 2019
    Assignee: OVID THERAPEUTICS INC.
    Inventor: Matthew During
  • Patent number: 10195166
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hepatitis C virus (HCV) infectious disease. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating HCV infectious disease or an antiviral composition for HCV, containing at least one selected from the group consisting of: GRIM19 protein or a fragment thereof; and a gene encoding the protein or a fragment of the protein.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: February 5, 2019
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Seung Kew Yoon, Jung Hee Kim, Won Hee Hur, Mi La Cho, Jung Eun Choi, Eun Byul Lee
  • Patent number: 10195167
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: February 5, 2019
    Assignee: Glucox Biotech AB
    Inventors: Per Wikström, Erik Walum, Mona Wilcke
  • Patent number: 10195168
    Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: February 5, 2019
    Assignee: JAZZ PHARMACEUTICLAS IRELAND LIMITED
    Inventors: Clark P. Allphin, Michael DesJardin
  • Patent number: 10195169
    Abstract: A method of bio-matching a topical gel, cream or lotion includes selecting a vagina of a living body, identifying a secretion of the selected vagina, identifying a composition of the identified secretion, and formulating the topical gel to match the identified composition of the identified secretion.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: February 5, 2019
    Assignee: GOOD CLEAN LOVE, INC.
    Inventor: Wendy Strgar
  • Patent number: 10195170
    Abstract: Methods and compositions for inhibiting expression of ASC, expression of NLRP3, and/or formation of NLRP3 inflammasome complex by using diacerein or its analogs are provided. Also provided are methods and compositions for the treatment and/or prevention of a disorder mediated by ASC and/or NLRP3, and/or by formation of NLRP3 inflammasome complex by using diacerein or its analogs.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: February 5, 2019
    Assignee: TWI Biotechnology, Inc.
    Inventors: Chih-Kuang Chen, Jing-Yi Lee, Wei-Shu Lu, Carl Oscar Brown, III
  • Patent number: 10195171
    Abstract: Processes for producing a nutritional supplement that contains sulforaphane, and supplements formed thereby. Such a process includes combining a cruciferous vegetable, for example, broccoli sprouts, with strains of Lactobacillus, Streptococcus and Bifidobacterium to form a mixture, causing the mixture to undergo lactic acid fermentation, transform a glucosinolate within the cruciferous vegetable to sulforaphane, and yield a fermented mixture that contains sulforaphane, and then producing from the fermented mixture a supplement that can be ingested by an individual.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: February 5, 2019
    Assignee: CLOJJIC LLC
    Inventor: Anne-Marie Kosi-Kupe
  • Patent number: 10195172
    Abstract: Campylobacter are the commonest reported bacterial causes of gastroenteritis in the UK and industrialized worlds. This invention relates to a method of preventing or reducing the colonization of the gastrointestinal tract of an animal with Campylobacter. Accordingly, the present invention provides a method for disinfection of an animal comprising administering to said animal at least one compound that binds to MOMP or FlaA of Campylobacter in an effective amount to reduce the number of Campylobacter present in the gastrointestinal tract of said animal. The present invention also provides a method of preventing or reducing transmission of Campylobacter from one animal to another.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: February 5, 2019
    Assignee: Akeso Biomedical, Inc.
    Inventors: Jafar Mahdavi, Dlawer Ala'Aldeen
  • Patent number: 10195173
    Abstract: The specification provides compositions and methods to treat neurodegenerative diseases.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: February 5, 2019
    Assignees: Children's Medical Center Corporation, The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: Clifford J. Woolf, Brian Wainger, Evangelos Kiskinis, Kevin Eggan
  • Patent number: 10195174
    Abstract: The present disclosure provides methods for detecting the presence of a cancer stem cell and their use in cancer prognosis, evaluating risk of cancer metastasis, identifying or validating drug candidates, and determining treatment efficacy. It also provides kits useful for detecting the presence of cancer stem cells as well as methods of treating cancer using CAIX inhibitors.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: February 5, 2019
    Assignees: SIGNALCHEM LIFESCIENCES CORPORATION, BRITISH COLUMBIA CANCER AGENCY BRANCH
    Inventors: Paul C. McDonald, Frances E. Lock, Shoukat Dedhar
  • Patent number: 10195175
    Abstract: The present invention relates to combination therapy with ADCs against a tumor-associated antigen, such as Trop-2, and drugs, such as microtubule inhibitors and/or PARP inhibitors. Where ADCs are used, they preferably incorporate SN-38 or another drug that induces DNA strand breaks. Preferably, the combination of ADC and PARPi or microtubule inhibitor exhibits synergistic effects against the cancer. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: February 5, 2019
    Assignee: Immunomedics, Inc.
    Inventors: David M. Goldenberg, Thomas M. Cardillo
  • Patent number: 10195176
    Abstract: This invention is announcing a composition of flavonoid skeleton in the formula I or formula II compound, wherein each of the substituents is given the definition as set forth in the specification and claims. This composition have the capacity to treating or preventing a virus infection in a subject.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 5, 2019
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Hui-Chun Wang, Yang-Chang Wu, Fang-Rong Chang, Chin-Chung Wu
  • Patent number: 10195177
    Abstract: Uses of acyl-homoserine lactone compounds are described. In particular, uses of acyl-homoserine lactone compounds as anti-thrombotic agents, to inhibit platelets from becoming hypersensitive, and/or to prevent thrombosis, are described.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: February 5, 2019
    Assignee: The University of Toledo
    Inventors: Randall G. Worth, Glenn R. Westphal, Brenton R. Keeley, Leah M. Wuescher
  • Patent number: 10195178
    Abstract: Disclosed are compositions comprising (a) a GPR40 agonist and (b) an SGLT2 inhibitor, and methods for treating of disorders that are affected by the modulation of the GPR40 receptor and SGLT2 transporter. Such GPR40 compounds are represented by Formula (I) as follows: wherein ring W, R1, R2, R3, R5, R6, A, and Z, are defined herein.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: February 5, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Yin Liang, Keith T. Demarest
  • Patent number: 10195179
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: February 5, 2019
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Patent number: 10195180
    Abstract: The present disclosure provides novel formulations for treating foot or hand pain by topically administering a sympathomimetic drug, particularly oxymetazoline, to the skin of the foot or hand.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: February 5, 2019
    Inventor: Jennifer L. Sanders
  • Patent number: 10195181
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: February 5, 2019
    Assignee: Novartis AG
    Inventors: Kamlesh Jagdis Bala, Andrew Brearley, James Dale, Anne-Marie Edwards, Mahbub Ahmed, David Porter, Robert Alexander Pulz, Lisa Ann Rooney, David Andrew Sandham, Duncan Shaw, Nichola Smith, Jessica Louise Taylor, Roger John Taylor, Thomas Josef Troxler, Joe Wrigglesworth
  • Patent number: 10195182
    Abstract: A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. The formulated drug can also be administered together with one or more of other cancer therapeutic agents. A maintenance dosing is provided after the subject is free of cancer to insure the cancer eradication. Subjects with cancers of prostate, liver, lung, ovarian, and breast are preferably accepted for treatment.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: February 5, 2019
    Assignee: Ariagen, Inc.
    Inventor: Jiasheng Song
  • Patent number: 10195183
    Abstract: Disclosed herein are methods of treating conditions, which may be associated with elevated levels of mast cells, basophils, eosinophils, or a combination thereof, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: February 5, 2019
    Assignee: Knopp Biosciences LLC
    Inventors: Michael E Bozik, Steven Dworetzky
  • Patent number: 10195184
    Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.
    Type: Grant
    Filed: March 19, 2017
    Date of Patent: February 5, 2019
    Assignee: ANGION BIOMEDICA CORP.
    Inventors: Bijoy Panicker, Rama K. Mishra, Dong Sung Lim, Lambertus J. W. M. Oehlen, Dawoon Jung
  • Patent number: 10195185
    Abstract: 4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: February 5, 2019
    Assignee: Samumed, LLC
    Inventors: Sunil Kumar KC, David Mark Wallace, Jianguo Cao, Chandramouli Chiruta, Joseph Timothy Marakovits, Venkataiah Bollu, John Hood
  • Patent number: 10195186
    Abstract: The present invention is directed to N-substituted-5-substituted phthalamic acids which of formula (A). The compounds are considered useful for the treatment of diseases treatment of a neurodegenerative disease, psychiatric disease, motoneuron disease, peripheral neuropathies, pain, neuroinflammation or atherosclerosis such as Alzheimer's disease and Parkinson's disease.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: February 5, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Philip James Maltas, Stephen Watson, Morten Langgård, Laurent David
  • Patent number: 10195187
    Abstract: Transdermal therapeutic system and method of using the same for safely treating hypocholinergic disorders of the central nervous system such as Alzheimer type dementia. The transdermal therapeutic system comprises oxybutynin in combination with a cholinergic receptor agonist (CRA) such as xanomeline.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: February 5, 2019
    Assignee: Chase Pharmaceuticals Corporation
    Inventors: Thomas N. Chase, Kathleen E. Clarence-Smith
  • Patent number: 10195188
    Abstract: The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: February 5, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Petrus Bekker, Shichang Miao, Israel Charo, Tom Schall
  • Patent number: 10195189
    Abstract: This invention provides, among other things, tetrahydroisoquinolines useful for treating viral infections, pharmaceutical formulations containing such compounds, as well as methods of inhibiting the replication of a virus, such as HIV, or treating a disease, such as AIDS.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: February 5, 2019
    Assignee: Prosetta Antiviral, Inc.
    Inventors: Andy Atuegbu, Dennis Solas, Clarence R. Hurt, Anatoliy Kitaygorodskyy
  • Patent number: 10195190
    Abstract: Local delivery formulations of the antineoplastic and microbicide agent acriflavine, and methods of making and using thereof are significantly more efficacious at increasing the median survival of subjects with proliferative disease than systemic administrations of acriflavine. The local delivery formulations of acriflavine show a dose-dependent increase in the median survival of subjects. The local delivery forms provide the increased efficacy without the toxicity associated with systemic administration of the agent.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: February 5, 2019
    Assignee: The Johns Hopkins University
    Inventors: Henry Brem, Antonella Mangraviti, Alessandro Olivi, Betty M. Tyler, Tula Raghavan
  • Patent number: 10195191
    Abstract: The invention relates a composition comprising an opioid agonist and Compound-1:
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: February 5, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Patent number: 10195192
    Abstract: A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: February 5, 2019
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. Missling
  • Patent number: 10195193
    Abstract: The embodiments described herein include methods and formulations for treating viruses and diseases that are exacerbated by inflammatory responses in the body. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: February 5, 2019
    Assignee: IRR, Inc.
    Inventor: Bruce Chandler May
  • Patent number: 10195194
    Abstract: A method of promoting remyelination in a subject in need thereof includes administering to the subject a therapeutically effective amount of at least one (1,3) Diazole compound, wherein the therapeutically effective amount is the amount effective to induce endogenous oligodendrocyte precursor cell (OPC) differentiation in the subject's central nervous system.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: February 5, 2019
    Assignee: Case Western Reserve University
    Inventors: Paul Tesar, Fadi J. Najm, Robert H. Miller
  • Patent number: 10195195
    Abstract: The invention relates to Histamine H4 receptor antagonists or inhibitors of Histamine H4 receptor gene expression for the treatment and/or the prevention of vestibular disorders.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: February 5, 2019
    Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Gilles Desmadryl, Christian Chabbert
  • Patent number: 10195196
    Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 5, 2019
    Assignee: Novartis AG
    Inventors: Atwood Kim Cheung, Donovan Noel Chin, Natalie Dales, Aleem Fazal, Timothy Hurley, John Kerrigan, Gary O'Brien, Lei Shu, Robert Sun, Moo Je Sung
  • Patent number: 10195197
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: February 5, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Mark K. Bennett, Matthew I. Gross, Susan D. Bromley, Keith Orford
  • Patent number: 10195198
    Abstract: Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and sleep apnea. In certain embodiments provided are methods that include administering a compound of formula (I) as disclosed herein. In some embodiments provided are methods that include administering a P2X3 and/or a P2X2/3 receptor antagonist.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 5, 2019
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Anthony P. Ford, Julian Paton
  • Patent number: 10195199
    Abstract: A hair growth formulation includes minoxidil and foeniculum vulgare, atriplex nummularia extract, or a combination of foeniculum vulgare and atriplex nummularia extract. A method for increasing hair growth includes applying a hair growth formulation to a subject.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: February 5, 2019
    Assignee: Beautopia LLC
    Inventor: David Ben Kunin